How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Daniele Santini; Antonio Galvano; Francesco Pantano; Lorena Incorvaia; Sergio Rizzo; B. Vincenzi; L. Castellana; Giovanna Giuliana; Fiorella Guadagni; Francesca Toia; Giuseppe Tonini; Antonio Russo; Giuseppe Badalamenti; Viviana Bazan

doi:10.1016/j.critrevonc.2019.07.013

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Daniele Santini, Antonio Galvano, Francesco Pantano, Lorena Incorvaia, Sergio Rizzo, B. Vincenzi, L. Castellana, Giovanna Giuliana, Fiorella Guadagni, Francesca Toia, Giuseppe Tonini, Antonio Russo, Giuseppe Badalamenti, Viviana Bazan

Research output: Contribution to journal › Review article › peer-review

Abstract

Background: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods: we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results: our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions: Our findings support in clinical practice the 12-week schedule an alternative to the standard 4-week schedule in advanced breast and prostate cancer, in particular when the clinical comorbidities of the patients suggest a higher risk of renal failure or hypocalcaemia.

Original language	English
Pages (from-to)	68-75
Number of pages	8
Journal	Critical Reviews in Oncology/Hematology
Volume	142
DOIs	https://doi.org/10.1016/j.critrevonc.2019.07.013
Publication status	Published - Oct 2019

Keywords

AEs
Bone metastases
Breast
Meta-Analysis
Prostate
SMR
Solid tumors
Zoledronic acid

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.critrevonc.2019.07.013

Fingerprint Dive into the research topics of 'How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials'. Together they form a unique fingerprint.

Cite this

Santini, D., Galvano, A., Pantano, F., Incorvaia, L., Rizzo, S., Vincenzi, B., Castellana, L., Giuliana, G., Guadagni, F., Toia, F., Tonini, G., Russo, A., Badalamenti, G., & Bazan, V. (2019). How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 142, 68-75. https://doi.org/10.1016/j.critrevonc.2019.07.013

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. / Santini, Daniele; Galvano, Antonio; Pantano, Francesco; Incorvaia, Lorena; Rizzo, Sergio; Vincenzi, B.; Castellana, L.; Giuliana, Giovanna; Guadagni, Fiorella; Toia, Francesca; Tonini, Giuseppe; Russo, Antonio; Badalamenti, Giuseppe; Bazan, Viviana.

In: Critical Reviews in Oncology/Hematology, Vol. 142, 10.2019, p. 68-75.

Research output: Contribution to journal › Review article › peer-review

Santini, D, Galvano, A, Pantano, F, Incorvaia, L, Rizzo, S, Vincenzi, B, Castellana, L, Giuliana, G, Guadagni, F, Toia, F, Tonini, G, Russo, A, Badalamenti, G & Bazan, V 2019, 'How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials', Critical Reviews in Oncology/Hematology, vol. 142, pp. 68-75. https://doi.org/10.1016/j.critrevonc.2019.07.013

Santini, Daniele ; Galvano, Antonio ; Pantano, Francesco ; Incorvaia, Lorena ; Rizzo, Sergio ; Vincenzi, B. ; Castellana, L. ; Giuliana, Giovanna ; Guadagni, Fiorella ; Toia, Francesca ; Tonini, Giuseppe ; Russo, Antonio ; Badalamenti, Giuseppe ; Bazan, Viviana. / How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. In: Critical Reviews in Oncology/Hematology. 2019 ; Vol. 142. pp. 68-75.

@article{dd1c58f135a84876b4049eb009ce706d,

title = "How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials",

abstract = "Background: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods: we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results: our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions: Our findings support in clinical practice the 12-week schedule an alternative to the standard 4-week schedule in advanced breast and prostate cancer, in particular when the clinical comorbidities of the patients suggest a higher risk of renal failure or hypocalcaemia.",

keywords = "AEs, Bone metastases, Breast, Meta-Analysis, Prostate, SMR, Solid tumors, Zoledronic acid",

author = "Daniele Santini and Antonio Galvano and Francesco Pantano and Lorena Incorvaia and Sergio Rizzo and B. Vincenzi and L. Castellana and Giovanna Giuliana and Fiorella Guadagni and Francesca Toia and Giuseppe Tonini and Antonio Russo and Giuseppe Badalamenti and Viviana Bazan",

year = "2019",

month = oct,

doi = "10.1016/j.critrevonc.2019.07.013",

language = "English",

volume = "142",

pages = "68--75",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

AU - Santini, Daniele

AU - Galvano, Antonio

AU - Pantano, Francesco

AU - Incorvaia, Lorena

AU - Rizzo, Sergio

AU - Vincenzi, B.

AU - Castellana, L.

AU - Giuliana, Giovanna

AU - Guadagni, Fiorella

AU - Toia, Francesca

AU - Tonini, Giuseppe

AU - Russo, Antonio

AU - Badalamenti, Giuseppe

AU - Bazan, Viviana

PY - 2019/10

Y1 - 2019/10

N2 - Background: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods: we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results: our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions: Our findings support in clinical practice the 12-week schedule an alternative to the standard 4-week schedule in advanced breast and prostate cancer, in particular when the clinical comorbidities of the patients suggest a higher risk of renal failure or hypocalcaemia.

AB - Background: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods: we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results: our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions: Our findings support in clinical practice the 12-week schedule an alternative to the standard 4-week schedule in advanced breast and prostate cancer, in particular when the clinical comorbidities of the patients suggest a higher risk of renal failure or hypocalcaemia.

KW - AEs

KW - Bone metastases

KW - Breast

KW - Meta-Analysis

KW - Prostate

KW - SMR

KW - Solid tumors

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=85069976238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069976238&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2019.07.013

DO - 10.1016/j.critrevonc.2019.07.013

M3 - Review article

C2 - 31377434

AN - SCOPUS:85069976238

VL - 142

SP - 68

EP - 75

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this